ARROWHEAD PHARMACEUTICALS INC

NASDAQ: ARWR (Arrowhead Pharmaceuticals, Inc.)

Last update: 6 days ago, 2:20PM

47.78

0.63 (1.34%)

Previous Close 47.15
Volume 3,113,499
Price / Sales 15.01
Price / Book 134.18
52 Weeks Range
37.06 (-22%) — 95.49 (99%)
Profit Margin -26.41%
Operating Margin (TTM) 70.24%
Diluted EPS (TTM) -1.24
Quarterly Revenue Growth (YOY) -29.60%
Total Debt/Equity (MRQ) 108.23%
Current Ratio (MRQ) 5.15
Operating Cash Flow (TTM) 61.15 M
Levered Free Cash Flow (TTM) -6.46 M
Return on Assets (TTM) -5.86%
Return on Equity (TTM) -26.22%

AIStockmoo Score

-1.3
Weak profitability. Ample short-term liquidity. Negative cash flow. info
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Return on Capital info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
Uptrend over the past year. Far below its 52-week high. info
In a downtrend: the price is below its moving averages, and they are falling. It has dropped well below them. A recent move above resistance has not been confirmed. info
From our AI technical analysis of the chart. info NA
Candle Patterns info NA
No recent price targets, so based on how targets have been revised. info
Recent news mixed or neutral. info
Holdings' Sentiment info NA
Institutions net +1.69% of shares in their latest 13F filings: 257 holders increased, 268 decreased (quarter to 30 Sep 2026). info
Short interest +22.9% from 31 Aug to 30 Oct 2026, 8.5 days to cover (FINRA). info
Insider Activity info NA
Market environment cautious. info
Sector lagging the market.
The pillars agree, so the score is strengthened.
Earnings per share have gone up and down. Made a loss in recent years. info
Below its medium-term trend line. info
Price is low against its 52-week average. Down over 5 years. info
Short-term momentum falling. info
No clear signal from support and resistance. info
Final Score -1.29
Show all

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Arrowhead Pharmaceuticals, Inc. Mixed Bullish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
ARWR - - - 134.18 -1.3
SYRE 9 B - - 10.08 1.1
MDGL 9 B - - 14.74 -0.4
CORT 7 B - 47.78 8.89 -1.5
FOLD 5 B - - - 0.0
ARQT 3 B - 119.82 14.26 -0.1

Select this tab to load the latest available analysis.

Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.

Sector Healthcare
Industry Biotechnology
Investment Style Small Growth
% Held by Insiders 13.02%
% Held by Institutions 77.19%

No data within this time range.

No data within this time range.

Institutions

Institutional ownership: 96.54%

Positions Holders Shares
Increased 257 14,798,342
Decreased 268 13,553,768
New 83 4,488,008
Sold out 84 3,346,457

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 11,583,518 8.5
15 Oct 2026 10,959,276 5.4
30 Sep 2026 10,760,463 4.0
15 Sep 2026 9,272,290 5.1
31 Aug 2026 9,426,449 8.8
14 Aug 2026 9,207,426 7.8

FINRA short interest via Nasdaq, reported twice a month.

3 Positive 2 Negative 6 Neutral
Date Type Details
13 Nov 2026 Yahoo Finance Arrowhead (ARWR) Q4 2026 Earnings Call Transcript
Plozasiran launch prep and a multibillion sHTG opportunity come into focus.
12 Nov 2026 Yahoo Finance Arrowhead Pharmaceuticals Q4 Earnings Call Highlights
Arrowhead Pharmaceuticals (NASDAQ:ARWR) is preparing for a potential U.S. launch of its drug REDEMPLO in a larger patient population in the second quarter of 2027, as the company works to turn growing prescription demand for the medicine into paid treatments. On its fiscal 2026 earnings call, manag…
12 Nov 2026 Yahoo Finance Arrowhead Pharmaceuticals falls on earnings miss
Investing.com -- Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) reported fiscal year 2026 results that fell short of Wall Street expectations, with the stock declining 2.4% in after-hours trading Thursday.
12 Nov 2026 Yahoo Finance Arrowhead Research: Fiscal Q4 Earnings Snapshot
(AP) — Arrowhead Research Corp. (ARWR) on Thursday reported a loss of $428 million in its fiscal fourth quarter.
12 Nov 2026 Yahoo Finance Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results
PASADENA, Calif., November 12, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2026 fiscal year ended September 30, 2026. The Company is hosting a conference call today, November 12, 2026, at 4:30 p.m. ET to discuss the results.
09 Nov 2026 Yahoo Finance Is Arrowhead Pharmaceuticals (ARWR) Worth Its Price After UK Approval?
Arrowhead Pharmaceuticals has had a bumpy share price journey lately, which puts a fresh spotlight on one simple question for investors who follow drug developers that rely heavily on future product uptake: is today’s valuation supported by its sales base? Over the past 3 years the stock has…
09 Nov 2026 Yahoo Finance Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
PASADENA, Calif., November 09, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events:…
07 Nov 2026 Yahoo Finance Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates
PASADENA, Calif., November 07, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results on two of the RNA interference (RNAi) based therapies in its cardiometabolic pipeline at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago. The presentations included…
04 Nov 2026 Yahoo Finance Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity
PASADENA, Calif., November 04, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed a refinancing with funds managed by Sixth Street that lowers its borrowing costs, improves near-term liquidity, extends its debt maturity, and increases financial and…
03 Nov 2026 Yahoo Finance Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results
PASADENA, Calif., November 03, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 12, 2026, at 4:30 p.m. ET to discuss its financial results for the 2026 fiscal year ended September 30, 2026…
02 Nov 2026 Yahoo Finance Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026
PASADENA, Calif., November 02, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it will present important data at this week’s American Heart Association Scientific Sessions in Chicago.
31 Oct 2026 Yahoo Finance 3 Biotech Stocks With Upside Of Up To 80%
Tech heavy indices have taken a hit as investors question huge AI spending, which leaves many traders searching for growth stories that are tied less to data centers and more to hard science. That is where high risk, high potential biotech stocks with solid finances come into focus. This article…
28 Oct 2026 Yahoo Finance Arrowhead gains UK marketing authorisation for Redemplo
The regulatory approval covers patients diagnosed through either genetic testing or clinical criteria.
27 Oct 2026 Yahoo Finance Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides
PASADENA, Calif., October 27, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that adults in England and Wales who live with a rare metabolic condition called Familial Chylomicronaemia Syndrome (FCS) will have access to a newly licensed new treatment option available on the NHS…
23 Oct 2026 Yahoo Finance Arrowhead Pharmaceuticals And 2 Biotech Stocks To Own
Biotech stocks live and die on access to capital, so the Federal Reserve’s signal that interest rates may pause for now gives this high risk corner of the market some breathing room. Cheaper money can make it easier to fund drug pipelines and clinical trials, which matters if you are hunting for…
16 Oct 2026 Yahoo Finance Arrowhead Pharmaceuticals (ARWR) Reports Fresh ARO MAPT Data, Is The Stock Still Cheap?
Arrowhead Pharmaceuticals (ARWR) drew fresh attention after announcing interim Phase 1/2a data for ARO-MAPT, which showed deep and durable cerebrospinal fluid tau reductions in healthy volunteers using subcutaneous RNA interference delivery across the blood brain barrier. Arrowhead Pharmaceuticals…
15 Oct 2026 Yahoo Finance ARWR: Interim ARO-MAPT Data Shows Potential for TRiM™ Platform in CNS Diseases
By David Bautz, PhD NASDAQ: ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Interim Data for ARO-MAPT Shows Promise for TRiM™ Platform in CNS Diseases On October 14, 2026, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced interim results for the Phase 1/2a study of ARO-MAPT, which is…
Show more

Recent Signals candle patterns and EMA crosses

▼ Death cross 7 sessions ago · 04 Nov
Long term · EMA 50/200
The 50-day EMA crossed below the 200-day, a widely watched sign that the long-term trend has turned down.

Technical Setup Medium

Trend order
Slope
Entry –
Volume
In a downtrend: the price is below its moving averages, and they are falling. It has dropped well below them. A recent move above resistance has not been confirmed.
Nearest support: 45.68 – 47.22 · moderate level
Nearest resistance: 53.25 – 57.33 · strong level

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Risk / Reward
TP1:
TP2:

Loss to SL against profit to each target, from EP. A ratio of 2 or more is usually sought.

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria